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1  INTRODUCTION
The role of psychotherapy in mental health services has been questioned, both in terms of
effectiveness and costs. The tendency of patients to continue in long term therapy (Follette
and Cummings, 1967) has meant that insurers and other funders have been reluctant to
provide this service. However, a number of studies have shown that outpatient psychotherapy
is associated with lower medical service use (Follette and Cummings, 1967; Schlesinger et al,
1983; Jameson et al, 1978; Goldberg et al, 1970; Mumford et al, 1984; Ginsberg, 1984;
Gabbard et al, 1997).Some commentators have argued that there is now a body of evidence
supporting the cost effectiveness of psychotherapy, at least in some conditions (Lazar and
Gabbard, 1997; Rainer, 1996). Most studies have used before/after designs and there are very
few randomised controlled trials (Healey and Knapp 1995). As Mumford and Schlesinger
(1987) point out, reductions in service use are not inevitable.
Borderline Personality Disorder (BPD) is a serious mental illness, with significant mortality
and morbidity. BPD is often associated with other personality disorders and social
dysfunction. Long term follow up studies have shown that most patients improve over time,
whilst short-term outcomes are less favourable (Carver 1997). Psychotherapy has been shown
to be of benefit in the treatment of BPD (McGrath, 1986) and there is some evidence that it is
also cost effective ((Lazar and Gabbard, 1997).
Economic evaluation requires the comparison of the costs and benefits of a health program or
service. In a full economic evaluation, both costs and benefits are measured. The most
frequently used method is cost effectiveness analysis in which benefits are measured in terms
of clinical outcomes, typically number of life years saved. Cost minimisation analysis is
sometimes described as a partial economic analysis as only costs are measured and benefits
are not considered. This form of analysis is appropriate when the outcomes of the program
being evaluated have been demonstrated to be better or as good as the alternative.
There have been few economic analyses of psychotherapy; research has focussed on
effectiveness while ignoring considerations of cost or cost-effectiveness (McGrath, 1994).
Where cost has been a consideration, for the most part a lower use of health services has been
taken to imply overall cost savings (Gabbard et al, 1997 ). However, Chisholm (1998)
reported on the basis of three trials that when the cost of psychotherapy was added to other
health service costs, the net impact of psychotherapy was cost neutral. These results must beEconomic Analysis of Psychotherapy
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interpreted with caution as even the randomised controlled trials consisted of small samples,
while other studies were of less rigorous research design. In the Australian context, Stevenson
and Meares (1992) have demonstrated fewer hospital admissions and lower lengths of stay,
fewer medical visits and reduced drug use over twelve months in BPD patients treated with
psychotherapy. However, the initial study had not examined whether the cost savings due to
reduced health service use were sufficient to offset the intensive period of psychotherapy.
Yates and Newman (1980) point out that there are substantial differences in the cost of
providing psychotherapy and that this cost is a major determinant of the cost-effectiveness.
The purpose of this study was to examine the cost effectiveness of a particular type of
psychotherapy developed by Russell Meares as an extension of the Stevenson and Meares
study. It was commissioned by the Department of Psychiatry at Westmead Hospital with
support from the Royal Australian and New Zealand College of Psychiatrists. A cost
minimisation analysis is appropriate as improved health outcomes from this psychotherapy
had already been demonstrated.
2  METHODS
The aim of this analysis was to compare the costs of treating BPD with psychotherapy versus
conventional care. Psychotherapy was continued over a twelve month period. Data were
collected on health service use for twelve months prior to commencing psychotherapy and
twelve months after the completion of the course of psychotherapy. Use of health services in
the twelve months before psychotherapy were assumed to represent conventional care. It
would be expected that during the psychotherapy treatment period, use of health services
would be changing, either due to psychotherapy displacing other health service use or a
gradual reduction in health service use as health state improved. Hence the use of services in
the twelve months after the completion of psychotherapy is more representative of the
outcome achieved. Therefore the net costs of psychotherapy were defined as the costs of
health care for twelve months after psychotherapy was completed plus the cost of the
psychotherapy less the cost of conventional care.
Patients whose hospital admission costs before psychotherapy were $10,000 or greater were
classified as high users of health services. Results are shown for all patients and for high user
and low user sub-groups.Hall, Caleo and Stevenson
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2.1  Identification of costs
The perspective taken is that of the health service, ie only health service costs are included.
Costs to patients and their families are not included.




ambulatory care including visits to general practitioners, specialists, psychologists, social
workers, physiotherapy, dietitians;
diagnostic tests;
medications, prescription and over the counter.
Patient sample
This project was an extension of the previous study by Stevenson and Meares. Thirty patients
with BPD were included in the study and completed  twelve months of psychotherapy.
Recruitment and eligibility criteria are described elsewhere (Stevenson and Meares, 1992).
Data collection
In the initial study, patients were asked, at interview before commencing psychotherapy, to
recall their service use over the previous twelve months. Similarly, they were asked at follow
up twelve months after completing psychotherapy, to again recall service use over the
previous twelve months. In this study, Westmead medical records for all patients enrolled in
the study were reviewed and data on service use extracted by one of the investigators (JS).
Medical record data were used in preference to patient recall where they were available.
For each patient, GP visits and psychiatrist visits were compared with prescription
medications, as patients need to visit a medical practitioner to obtain prescriptions. In a
number of cases, the number of medical visits provided by recall were fewer than those
implied by the medication use data. Where this was so, additional GP visits were imputed to
ensure consistency with the medication use data. In one case where the medication can onlyEconomic Analysis of Psychotherapy
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be prescribed by a specialist, one specialist visit was imputed. The results are shown both
including and excluding imputed medical visits.
2.2  Unit costs
Psychotherapy
Each patient attended two x one hour treatment sessions weekly. Each session was one to one
and administered by a trainee therapist. The trainees were psychiatric registrars, nurses and
psychologists who were participating in a training course being developed at Westmead
Hospital. As these were trainee therapists, additional supervision was required. Trainees met
in groups of three with a supervising psychiatrist for one hour each week during which six
patients (two per trainee) were reviewed. Therefore the additional training time was allocated
over the twelve sessions per week.
Hourly wage rates according to public hospital awards were provided by Westmead Hospital.
Superannuation and other on-costs were included. More details are given in Appendix 1.1.
This gave a cost per hour of therapy of $43.35.
However, if psychotherapy for BPD was adopted more widely, it is not clear that all the
therapy could be provided under the training program. An alternative means of providing
psychotherapy is through specialist psychiatrists. This gives an alternative cost, based on the
MBS scheduled fee, of $130.70 per session.
Emergency visits
Visits to Accident and Emergency were assigned an AN-DRG code where possible. The
difference between the AN-DRG weighted cost including emergency care and the AN-DRG
weighted cost without emergency care was used as the cost of an emergency visit for that AN-
DRG. Where the reason for visit could not be coded, then the cost was estimated at the
average cost (over all AN-DRGs) including emergency less the average cost excluding
emergency. This gave a cost per emergency visit from $70.23 to $272.30 (appendix 1.2)
Ambulatory care
Visits to general practitioners and to specialists were costed using MBS fees. The cost used
was the average MBS fee weighted according to frequency of that type of visit in the generalHall, Caleo and Stevenson
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population. Frequency data were provided by the Health Insurance Commission. This gave an
average cost per GP visit as $26.50 and for a specialist visit as $87.50. More details are in
Appendix 1.3.
The cost of outpatient visits was taken from a draft report provided by NSW Health (details
shown in Appendix 1.3). Costs are separated into new and repeat visits. The mean new visit
cost varies from $16.00 (physiotherapy) to $35.00 (psychology).
Diagnostic tests
Costs used were taken from the MBS fees. The costs used are shown in appendix 1.4.
Inpatient care
Acute inpatient admissions were classified according to the Australian Diagnosis Related
Groups (AN-DRG version 3). Cost weights were taken from NSW Health (1998). Where two
or more AN-DRG codes could apply to a particular admission, the least costly option was
selected. Relevant costs are shown in Appendix 2.
Medications
Costs for medication during hospital stays were not counted as these are already included in
the AN-DRG cost weights. Where dosage was not recorded, the lowest dose appropriate was
determined by advice from a psychiatrist. Where dose and strength was not recorded, the cost
was not included. Where an antibiotic was prescribed but not specified, it was assumed to be
amoxyllin, the most commonly prescribed broad spectrum antibiotic and less expensive than
newer classes of antibiotics.
Costs were as given in the Schedule of General Pharmaceutical Benefits for Approved
Pharmacists and Medical Practitioners (1 November 1997) for the “dispensed price for max.
qty”. Cost was rounded up to the minimum purchase quantity. Patient co-payments were not
included (details in appendix 3).
Some medications recorded were no longer available. Where the drug was still listed on the
Repatriation Schedule of the PBS, this cost was used. Otherwise, the wholesale price was
obtained from the archives of Australian Pharmaceutical Industries Ltd, or from the
manufacturer. 10% margin plus $4.34 dispensing fee was added to the wholesale price.Economic Analysis of Psychotherapy
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The cost of over the counter medications was based on the listed pharmaceutical wholesale
price plus 50%.
3  RESULTS
There was a saving of approximately $670,000 in the costs of health services after the
psychotherapy program. Table 1 shows the costs by service type.
The net difference in the costs of treatment must take into account the cost of psychotherapy.
It was assumed that 50 sessions of psychotherapy would be provided over twelve months. The
cost of psychotherapy was estimated on the basis of using trainee therapists; and using
consultant psychiatrists. The former cost $4,335 per patient, and the latter $13,070. This cost
was added to the costs of health service use after psychotherapy and the net difference
between that and service use before psychotherapy was calculated.  The results are shown in
Table 2.
TABLE 1: CHANGE IN HEALTH SERVICE USE
Before After Saving
Inpatient care  $683,977 $41,424 $642,553
Emergency visits  $15,327  $3,454 $11,873
Ambulatory care $43,853 $40,339  $3,514
Diagnostic tests  $2,565  $112 $2,453
Medications $20,067  $3,901  $16,166
Total $765,789 $89,230 $676,559Hall, Caleo and Stevenson
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Conventional care $765,789 $765,789
Psychotherapy $392,000 $130,050
After therapy $89,230 $89,230
Net saving $284,559 $546,509
The results show that overall the psychotherapy program was cost saving. After the program,
health care costs for this group of patients were around $89,000 for twelve months, a
reduction of approximately $670,000. This more than offsets the costs of the program using
trainee psychotherapists, giving net savings of over $500,000 over one year. Even using
consultant psychiatrists, the program is associated with net savings over one year.
3.1  Costs of care by high and low users
Inpatient hospital treatment is the greatest component of the total cost, 90% of total costs
before psychotherapy, and  45% after. However, this varies enormously across individuals
from a number of patients who had no admissions, and therefore zero cost, to one patient who
incurred costs of almost $150,000. The distribution of hospital costs is bimodal, with a
number of patients incurring low or zero costs, and another group who appear to be high users
of hospital services (see Figure 1). Consequently, the group was disaggregated into high
users, those who incurred over $10,000 per annum in hospital costs (n = 12), and low users
who incurred less than $10,000 per annum in hospital costs (n = 18).  High users were
responsible for approximately 90% of all hospital costs.
The costs of conventional care (ie before the psychotherapy program) by type of service and
disaggregated by high and low users  are shown in Table 3.Economic Analysis of Psychotherapy
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Inpatient care  $3,668 $51,497 $22,799
Emergency visits $266 $878 $511
Ambulatory care $1,622 $1,221 $1,461
Diagnostic tests $80 $94 $85
Medications $706 $613 $669
Total $6,360 $54,315 $25,555
The costs of health service use following psychotherapy, again disaggregated into the same
groups, still described as high and low users, are shown in table 4.








Inpatient care $268 $3,400 $3,051 $48,446 $1,380
Emergency visits $57 $20 $202 $676 $115
Ambulatory care $1,656 $34 $877 $344 $1,344
Diagnostic tests $0 $80 $9 $85 $4
Medications $102 $604 $172 $441 $130
Total $2,102 $4,258 $4,322 $49,992 $2,973
Hospital costs are the largest component of total costs, and the largest component of the costs
of high service users. Twenty one patients had no hospital admissions in the year following
psychotherapy; for the nine who were admitted, hospital costs ranged from $1,300 to $12,000.Hall, Caleo and Stevenson
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While overall the psychotherapy program was associated with reduced costs, the results for
previously low users of health services are more equivocal. For low users, the costs of the
psychotherapy are about the same as the savings in health service use, with psychotherapy
costed at trainee rates. However, if the reduction in health service use continues beyond the
first year, then the savings outweigh the costs (see Table 5).
TABLE 5:  NET AVERAGE COSTS OF PSYCHOTHERAPY USING TRAINEE THERAPISTS BY
LOW AND HIGH USERS
Low users High users
Cost saving $4,258 $49,992
Psychotherapy $4,335 $4,335
Net difference $(77) $45,657
Net difference after 2 years $4,181 $95,649
3.2  Reliability of data
In the initial study, data on service use were collected by asking patients to recall their service
use over 12 months. The validity of data collected this way, particularly in this group of
patients, is not known. However, 12 month recall is generally considered of poor validity for
frequent events such as medical consultations and medication use, although it has more
validity for infrequent events such as hospital admission. In this study, data on service use
were collected from Westmead hospital records; these covered use of services provided by
Westmead Hospital. For services provided elsewhere, patient recall was used. The
comparison of Westmead record data with patient recall can provide some evidence of data
validity. The number of events reported in patient recall should be greater than or equal to the
number obtained from Westmead records for the two data sources to be consistent. The
proportion of patients giving consistent responses ranges from 20% to 40% (table 6). The
proportion of inconsistent responses and the extent of the inconsistency, up to 5 hospital
admissions unreported, raises doubt about the validity of the data.Economic Analysis of Psychotherapy
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TABLE 6: CONSISTENCY OF RESPONSES
Before After
Hospital admissions 37% 20%
Medical consults 30% 40%
Therefore, the results were re-estimated excluding inconsistent responses (table 7).
TABLE 7: CHANGE IN AVERAGE COSTS OF HEALTH SERVICE USE
Before After Saving
Inpatient care $12,125 $781 $11,344
Emergency visits $458 $96 $362
Ambulatory care $1,240 $1,569 $(328)
Diagnostic tests $75 $6 $69
Medications $554 $122 $432
Total $14,452 $2,574 $11,879
The savings due to the reduction in health care costs remain, although the amount saved is
halved. This amount covers the costs of the psychotherapy when provided by trainees.
However, if the therapy were to be provided by consultant psychiatrists the costs would be
almost the same as the savings in the reduction of health care use over one year.
3.3  Sensitivity analysis
It is generally accepted that the effect of varying key parameters on the results should be
analysed. In particular, where estimates are uncertain this shows how robust the results are to
variation in those estimates.
The cost of the psychotherapy was estimated from the program as it was functioning at
Westmead Hospital, that is using trainee therapists. There may be insufficient trainees to meetHall, Caleo and Stevenson
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the needs of an expanded program. Therefore, the costs of the program were estimated if
consultant psychiatrists were used; and the results for high and low users are shown in table 8.
The length of time over which reduced health service use would have to continue to be
equivalent to the cost of the program is also shown.
TABLE 8:  NET AVERAGE COSTS OF PROGRAM GIVEN BY PSYCHIATRISTSBY LOW AND
HIGH USERS
Low users High users
Cost saving $4,258 $49,950
Psychotherapy $13,070 $13,070
Net difference $(8,812) $36,880
Years taken to recoup costs 3.04 0.26
The costs of medical visits included a number of visits which were imputed from the reported
data on medications; this occurred when the specific medication usage reported could not be
prescribed without a consultation. This may reflect the fact that prescription drugs were able
to be obtained without a consultation; alternatively it may reflect errors in patient recall. The
cost estimates based on actual visits reported are shown in table 9. For most patients in the
study there were no imputed visits, that is their reported doctor visits were consistent with
their reported consultations. In the cost estimates before the psychotherapy program, there
was one patient who accounted for over $7,000 of imputed costs; and after one (other) patient,
for over $1,000 of imputed costs. The results are shown with these two outliers excluded.Economic Analysis of Psychotherapy
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TABLE 9: COSTS OF AMBULATORY CARE - REPORTED VISITS
Before After
No of patients with no
imputed visits
23 24
Cost of ambulatory care $43,853 $40,339
Cost without imputed visits $35,260 $38,007
Cost without outliers $36,539 $39,173
The impact of one or a small number of patients whose service use patterns fall widely
outside the range of service use for the rest of the group can be substantial, particularly when
the size of the group is relatively small. In this group of patients, there was one whose
hospital admissions were costed at almost $150,000 in one year. This compares with the
average for the rest of the group of $18,500. As hospital costs are the largest component of
total costs, this one patient could have an undue effect on the group results. Therefore the
results were re-estimated with the exclusion of this one outlier and are shown in tables 10 and
11.
TABLE 10:  CHANGE IN HEALTH SERVICE USE COSTS EXCLUDING OUTLIER
Before After Difference
Inpatient care $540,220 $39,895 $500,325
Other $80,377 $46,333 $34,044
Total $620,597 $86,228 $534,369Hall, Caleo and Stevenson
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TABLE 11:  CHANGE IN AVERAGE HEALTH SERVICE USE COSTS FOR HIGH USE PATIENTS
EXCLUDING OUTLIER
Before After Difference
Inpatient care $43,109 $3,189 $39,920
Other $2,930 $1,240 $1,690
Total $46,039 $4,429 $41,610
Whilst this one patient was responsible for the majority of hospital costs before the
psychotherapy program, the exclusion of this outlier does not affect the overall results. There
remains a substantial reduction in the costs of health service use, largely in hospital
admissions, after the psychotherapy program.Economic Analysis of Psychotherapy
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4  DISCUSSION
This study group comprised 30 patients and comprised a before/after design. Therefore it does
not overcome criticisms of other work in this area. As such, the results must be regarded with
caution.
These results show a substantial cost saving in the use of health services after a one year
program of psychotherapy. The exclusion of individuals with extremely high service use
reduces the amount of the savings but not substantially. The psychotherapy program was
costed based on the costs of trainee therapists. In an expansion of the program, or
development of a similar program elsewhere, it may not be feasible to use trainee staff.
Therefore, the program was also costed using consultant psychiatrists. Even at this higher
cost, the program appears to reduce net costs.
However, most of the cost data are developed from recall of service use. In this study, data
were verified by checking Westmead Hospital records. Data were judged as consistent when
the hospital records service use is at least as great as the data provided by patient recall. On
this criterion, 30% to 40% patient data are inconsistent. The true figure is likely to be higher
as this criterion can only assess under-reporting. The reliability of the data are of particular
concern, as there is the potential for bias. Patients recalling service use to an investigator who
is involved in service delivery are likely to attempt to please the investigator which in this
instance would be lower reporting of service use after the psychotherapy. On the other hand,
patients with borderline personality disorder may have more accurate recall after therapy. The
hospital admission data have more consistent responses in the ‘after’ period; however, for
medical consultations, the ‘after’ responses are less consistent (table 6). When the results are
re-estimated excluding the known inconsistent (ie for under-reporting) results, the net cost
savings are modest (for a program delivered by trainees) to neutral (for a program delivered
by psychiatrists). We have no way of testing the data for over-reporting. But if there is
substantial over-reporting in the ‘before’ period compared to the ‘after’ period, then the cost
savings would be over-estimated. This means the results must be interpreted with great
caution.   However if these savings continue to accrue over future years, the net savings will
increase.  These figures continue to be collected and will be reassessed at a future date.
The results have also been disaggregated according to whether patients were initially high
users of hospital services.  For high users, there is on average a substantial net cost saving;Hall, Caleo and Stevenson
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however, for low users the cost difference was neutral. This suggests that further work to
identify those patients who stand to benefit most from this form of therapy  may be useful.
The program may be cost effective, even if the net cost result at the end of one year is neutral.
If the reduction in health service use is continued into the future without further
psychotherapy, then the stream of cost savings may outweigh the cost of the program. If the
health outcomes from the program are improved, then even an increase in net costs may be
justified.
This analysis cannot unequivocally conclude that psychotherapy for BPD patients is cost
saving or cost effective. The evidence presented here suggests that it may be. The study is
limited by a small sample of patients, the unreliability of the data, and the before/after study
design. The results also suggest that it may be possible to identify a sub -group of BPD
patients who will benefit from psychotherapy. Further research is required to develop
evidence based recommendations.Economic Analysis of Psychotherapy
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APPENDIX 1: DERIVATION OF UNIT COST DATA
1.1 Cost of psychotherapy
Cost of trainees’ time is the weighted average hourly cost (salary plus oncosts) assuming that
trainee psychiatrists, nurses and psychologists gave equal numbers of psychotherapy sessions.
Hourly cost of trainee psychiatrist $26.78
Hourly cost of nurse $22.83
Hourly cost of psychologist $26.17
Average hourly cost $25.26
Supervision costs were the one hour meeting of three trainees with a supervising psychiatrist
each week. This session involved one hour of the psychiatrist’s time and three hours of the
trainees’ time. It was assumed that supervision time could be allocated equally over all
therapy sessions, ie 12 per week.
Hourly cost of psychiatrist $141.30
Weekly cost of supervision $217.08
Cost of supervision per session $ 18.09
Average cost of one hour of therapy  $ 43.35
1.2 Cost of accident and emergency visits
AN-DRG no. Title Cost
885 Injuries age < 65 $272.30
861 Drug intoxication and withdrawal $175.43
847 Personality disorders and acute reactions $ 70.23
932 Signs and symptoms $171.70
261 Chest pain $260.55
464 Signs & symptoms, muscl sys & conn $159.37
tiss age < 70 w/out cc
668 Menstrual & other fem reprod age <70 $121.81
W/out cc
Unspecified $ 86.00Hall, Caleo and Stevenson
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1.3  Cost of ambulatory medical care
GP Visits
Item No.          No. of services (1996/7)          Fraction of total                       Cost
   23 74,434,236         0.90968           $ 24.70
   36                               7,390,687                       0.09032                          $ 44.65
Total:                           81,824,923
Weighted cost for GP visit                                                                        $ 26.50
Specialists
Item No.          No. of services (1996/7)          Fraction of total                       Cost
  104                              3,968,706                      0.26692                         $ 63.90
  105    5,078,097         0.34153                         $ 32.00
  106          104,632                      0.00704                         $ 52.60
  110                               1,433,994                      0.09644                         $112.65
  116                            4,170,236         0.28047        $ 56.40
  119                                   113,081                      0.00761                         $ 32.00
Total:                            14,868,746
Weighted cost for Specialist visit          $ 87.05
References:(1) Medicare estimates and statistics for 1996/97
(2) Medicare Benefits Schedule Book, 1 November 1997
1.4 Other Outpatient Visits
                 Mean cost   Mean cost
New visits Repeat visits
Physiotherapy     $   16.00 $   12.00
Social Work $   27.00 $   21.00
Dietitian $   17.00 $     9.00
Psychology $   35.00                      $   26.00
Ref: Ambulatory Survey of Selected NSW Public Hospitals: Outpatient Services (Draft
Document) NSW Health Department, FebruaryEconomic Analysis of Psychotherapy
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1.5 Outpatient diagnostic tests
Item No.
Chest x-ray $ 37.20 66225
Plain abdominal x-ray $ 37.60 58900
Full blood count $ 17.20 65007
Thyroid function tests $ 41.00 66329
Liver function tests $ 19.80 66211
Biochemistry $ 19.80 66211
Lung function test                                $103.50 11503
ECG $ 23.30 11700
Wrist x-ray $ 41.85 57509
Urine examination $ 20.55 69217
Bone Scan $ 78.60 12306
Abdominal ultrasound $100.45 55036
Mammogram $ 49.70 59303
Breast Ultrasound $100.45 55034
Breast biopsy $103.00 30363
Urea $    9.55 66201
Creatinine $    9.55 66201
Barium meal $116.10 58912
CMV, Monospot $ 13.90 69229
Electrolytes $ 15.70 66207
Syphilis serology $ 34.70 69281
Hep A and Hep B $ 24.70 69276
Igm $ 14.85 71067
Ref: Medicare Benefits Schedule Book, 1 November 1997.
Commonwealth Department of Health and Family Services: AGPSHall, Caleo and Stevenson
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APPENDIX 2: HOSPITAL ADMISSION COST DATA
Costs for selected AN-DRGs
Cost Total Cost  Trim Point Outlier per Diem
No.AN-DRG Title                                         Weight           ($)       (in days )              Payment($)
846 Eating & obsessive-compulsive disorders 2.96 $7,296.40       60   $300
847 Personality disorders & acute reactions  0.54 $1,331.10 12      $350
861 Drug intoxication and withdrawal  1.21 $2,982.65 20      $425
932 Signs & symptoms  0.89 $2,193.85 15       $350
675  Vaginal delivery with moderately
         complicating diagnosis  0.91 $2,243.15 11      $500
686 Other antenatal admission with moderate
or no complicating diagnosis 0.37 $   912.05  6      $400
683 Abortion + D&C, aspiration curettage or
hysterectomy 0.32 $   788.80  1      $375
684 Pre-term labour 0.21 $   517.65  1      $475
661 Diagnostic curettage &/or diagnostic
hysteroscopy 0.33 $   813.45  4      $375
674 Vaginal delivery without complicating
diagnosis 0.74 $1,824.10 10      $500
663 Other feminine reprod. System O.R.
Procs age <65 w/o malignancy w/o cc 0.53 $1,306.45 11     $475
 42 Viral Meningitis 0.08 $1,972.00 10      $400
347 Abdominal pain or mesenteric adenitis
w/o cc 0.39 $   961.35  6      $350
187 Bronchitis & asthma age <50 w/o cc 0.43 $1,059.95  6      $350
557 Minor bladder procedures w/o cc 1.01 $2,489.65 12      $450
319 Abdominal, hernia and other umbilical
procedures age >9 1.01 $2,711.50 10      $425
863 Other drug use disorder & dependence 0.75 $1,848.75 12      $350
 47 Seizure age <65 w/o cc 0.41 $1,010.65   6      $300
314 Appendectomy w/o complicated
principal diagnosis 0.92 $2,267.80   7      $425
422 Soft tissue procedures 0.96 $2,366.40   9      $450
885 Injuries age <65 0.04 $   986.00   6      $325
128 Dental extractions and restorations 0.32 $   788.80   4     $375
335 Other colonoscopy w/o cc 0.03 $   739.50 11      $450
183 Pneumothorax w cc 1.71 $4,215.15 18      $425
Reference: NSW Health 1998. Technical Paper, Structural and Funding Policy Branch. The
Casemix Standards.Economic Analysis of Psychotherapy
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APPENDIX 3: MEDICATIONS COSTS
Generic Name of Drug       Strength     Quantity     No. of Brand names Disp. Price
                                                                                    Repeats                                        For max. qty.
Benztropine 2mg 60 2 Cogentin $ 6.88
Trifluoperazine 2mg 100 5 Stelazine $ 8.41
Trifluoperazine 5mg 100 5 Stelazine $ 8.41
Chlorpromazine 100mg 100 5 Largactil $12.78
Amozycillin 500mg   20 1 Amoxil $11.77
Naproxen 500mg   50 3 Naprosyn $14.45
Naproxen 250mg 100 3 Naprosyn $16.78
Indomethacin  25mg 100 3 Indocid $10.20
Codeine phosphate  30mg
with  paracetamol l500mg  20 0 Panadeine Forte $  6.86
Codeine   30mg
with aspirin 500mg   20 0 Codral Forte $  6.87
Carbamazepine 400mg 200 2 Tegretol $65.72
Thioridazine  10mg 100 5 Melleril $  8.21
Thioridazine  25mg 100 5 Melleril $  9.71
Thioridazine  50mg 100 5 Melleril $10.08
Thioridazine 100mg 100 5 Melleril $13.62
Diazepam    5mg   50 0 Valium $ 7.86
Temazepam  10mg   25 0 Normison $ 7.34
Amitriptyline  25mg  50 2 Tryptanol $ 6.61
Nitrazepam    5mg  25 0 Mogadon $ 7.34
Clomipramine  25mg  50 2 Anafranil $19.83
Oxazepam  30mg   25 0 Serepax $ 7.29
Phenelzine  15mg   50  2 Nardil $13.25
Tranylcypromine  10mg  50 2 Parnate $13.25
Lithium carbonate 250mg 200 2 Lithicarb $11.44
Trimipramine  50mg  50 2 Surmontil $ 7.16
Imipramine  25mg  50 2 Tofranil $ 6.63
Dothiepin  25mg   50  2 Prothiaden $ 8.43
Doxepin  25mg  50 2 Sinequan $ 7.44
Desipramine  25mg  50 2 Pertofran $ 7.42
Pindolol    5mg      100 5 Visken $12.22
Aluminium/magnes. Susp. 500mls       2  5 Mylanta $11.58
Cimetidine 200mg 120 5 Tagamet $32.43
Paracetamo l500mg 100 1 Dymadon $ 7.48
Codeine Phosphate  30mg   20 0 $ 9.07
Metronidazole 200mg  21 1 Flagyl $ 8.34
Clomiphene  50mg  10 5 Clomid $43.22
Salbutamol      2 5 Ventolin $10.70
Beclomethasone 100mg    1 5 Becotide 100 $17.07
Theophylline 250mg 100 5 Nuelin SR $11.16
From the Schedule of Pharmaceutical Benefits - November 1997Hall, Caleo and Stevenson
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Medications that were listed as General Pharmaceutical Benefits at the time of the study
Generic Name of Drug                   Strength     Quantity      No. of Brand names Disp. Price
                                                                                                    Repeats                                                         For max. qty.
Carbamazepine 400mg 200 2 Tegretol $65.72




Codeine + paracetamol 8mg-500mg    50 2 Dymadon Co. $9.43
Codeine + aspirin 8mg-500mg    50 2 Aspalgin $9.47
Private prescriptions
Flunitrazepam    2mg    2 5 Rohypnol $11.20
100 Digesic $31.95
100 Nembudine $26.95
   10mg 100 Librium $23.00
     1mg  50 Ativan $26.95
OTC medications
Codeine + paracetamol 8mg-500mg 100 Dymadon Co. $11.95
Mersyndol $ 7.50
Codeine + paracetamol 8mg-500mg 100 Panadeine $14.95
Paracetamol 100 Panadol $11.95
Aspirin 300mg  40 Aspro $ 5.95
1 Wholesale price provided by API
2 Wholesale price provided by Pharmacy Dept., Westmead Hospital